Timothy A. Springer, Director, 10% Owner at Cartesian Therapeutics, Inc. (RNAC), bought 37,912 shares at $16.86 ($660K) on 2025-01-13, disclosed to the SEC on 2025-01-15.
Open-market purchase of $660k RNAC by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.86 | 7,962 | $134K | 20.3% |
| 2 | $16.86 | 7,962 | $134K | 20.3% |
| 3 | $17.78 | 8,983 | $160K | 24.2% |
| 4 | $17.78 | 8,983 | $160K | 24.2% |
| 5 | $18.00 | 4,022 | $72K | 11.0% |
| Total | $17.42 avg | 37,912 |
| $660K |
| 100% |
| Filing → |
| TECX | BUY | 2025-04-09 | $17.1M | — | Filing → |
| RNAC | BUY | 2025-03-20 | $2.7M | — | Filing → |
| TECX | BUY | 2025-02-07 | $47.0M | — | Filing → |